![](/img/cover-not-exists.png)
56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results
Gettinger, S.N., Bazhenova, L.A., Salgia, R., Langer, C.J., Gold, K., Rosell, R., Shaw, A.T., Weiss, G.J., Dorer, D.J., Rivera, V.M., Kerstein, D., Camidge, D.R.Volume:
91
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/s0169-5002(16)30073-3
Date:
January, 2016
File:
PDF, 557 KB
english, 2016